Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020, 164(1):57-62 | DOI: 10.5507/bp.2019.009

Upregulation of miR150-5p in generalized myasthenia gravis patients is associated with decreased serum levels of IL-17 and increased serum levels of IL-10

Wenling Ao, Canhui Tian, Xiongjun He, Yeli Hu, Weidong Wang, Yajie Liu
Department of Neurology, Shenzhen Hospital, Southern Medical University, Shenzhen City, 518000, PR. China

Background: MiR150-5p has been reported to be involved in generalized myasthenia gravis, in which different cytokines play critical roles. The regulatory network of cytokines in generalized myasthenia gravis has not been fully elucidated. Our study aimed to investigate the interactions between miR150-5p and different cytokines in generalized myasthenia gravis. Materials and Method. Serum levels of miR150-5p and different cytokines including IL-2, IL-17, IL-10, IL-19, IL-20 and IL-35 were detected by qRT-PCR and ELISA, respectively. ROC curve analysis was performed to evaluate the diagnostic value of miR150-5p for generalized myasthenia gravis. Correlation between serum levels of miR150-5p and different cytokines were analyzed by Pearson correlation coefficient.

Results: Compared with healthy controls, decreased serum levels of IL-2 and IL-17 and increased serum levels of miR150-5p, IL-10, IL-19, IL-20 and IL-35 were observed in patients with generalized myasthenia gravis. Serum levels of miR150-5p were positively correlated with IL-10 and negatively correlated with IL-17. After treatments, serum levels of miR150-5p and IL-10 decreased, while serum levels of IL-2 and IL-17 increased.

Conclusion: Upregulation of miR150-5p is involved in generalized myasthenia gravis patients and is associated with decreased serum levels of IL-17 as well as increased serum levels of IL-10.

Keywords: generalized myasthenia gravis, MiR150-5p, cytokines

Received: July 13, 2018; Accepted: March 5, 2019; Prepublished online: March 29, 2019; Published: March 26, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ao, W., Tian, C., He, X., Hu, Y., Wang, W., & Liu, Y. (2020). Upregulation of miR150-5p in generalized myasthenia gravis patients is associated with decreased serum levels of IL-17 and increased serum levels of IL-10. Biomedical papers, 164(1), 57-62. doi: 10.5507/bp.2019.009
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015;14(10):1023-36. Go to original source... Go to PubMed...
    2. Westerberg E. Environmental Factors of Importance in Myasthenia Gravis. Emphasis on Physical Activity. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine. Acta Universitatis Upsaliensis; 2018.
    3. Meraouna A, Cizeron-Clairac G, Le Panse R, Bismuth J, Truffault F, Tallaksen C, Berrih-Aknin S. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 2006;108(2):432-40. Go to original source... Go to PubMed...
    4. Cufi P, Dragin N, Ruhlmann N, Weiss JM, Fadel E, Serraf A, Berrih-Sknin S, Le Panse R. Central role of interferon-beta in thymic events leading to myasthenia gravis. J Autoimmun 2014;52:44-52. Go to original source... Go to PubMed...
    5. Kanai T, Uzawa A, Kawaguchi N, Himuro K, Oda F, Ozawa Y, Kuwabara S. Adequate tacrolimus concentration for myasthenia gravis treatment. Eur J Neurol 2017;24(2):270-5. Go to original source... Go to PubMed...
    6. Iwakawa H, Tomari Y. The functions of microRNAs: mRNA decay and translational repression. Trends Cell Biol 2015;25(11):651-65. Go to original source... Go to PubMed...
    7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281-97. Go to original source... Go to PubMed...
    8. Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev 2015;87:3-14. Go to original source... Go to PubMed...
    9. Wang J, Zheng S, Xin N, Dou C, Fu L, Zhang X, Chen J, Zhang Y, Geng D, Xiao C, Cui G, Shen X, Lu Y, Wang J, Dong R, Qiao Y, Zhang Y. Identification of novel MicroRNA signatures linked to experimental autoimmune myasthenia gravis pathogenesis: down-regulated miR-145 promotes pathogenetic Th17 cell response. J Neuroimmune Pharmacol 2013;8(5):1287-302. Go to original source... Go to PubMed...
    10. Uzawa A, Kanai T, Kawaguchi N, Oda F, Himuro K, Kuwabara S. Changes in inflammatory cytokine networks in myasthenia gravis. Sci Rep 2016;6:25886. Go to original source... Go to PubMed...
    11. Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 2014;52:90-100. Go to original source... Go to PubMed...
    12. Punga T, Le Panse R, Andersson M, Truffault F, Berrih-Aknin S, Punga AR. Circulating mi RNA s in myasthenia gravis: miR-150-5p as a new potential biomarker. Ann Clin Transl Neurol 2014;1(1):49-58. Go to original source... Go to PubMed...
    13. Li Z Y. China guidelines for the diagnosis and treatment of generalized myasthenia gravis. Neurol Neuroimmunol Neuroinflamm 2016;3:1-9. Go to original source...
    14. Avidan N, Le Panse R, Berrih-Aknin S, Miller A. Genetic basis of myasthenia gravis-a comprehensive review. J Autoimmun 2014;52:146-53. Go to original source... Go to PubMed...
    15. Nogales-Gadea G, Ramos-Fransi A, Suarez-Calvet X, Navas M, Rojas-Garcia R, Mosquera JL, Diaz-Manera J, Querol L, Gallardo E, Illa I. Analysis of serum miRNA profiles of myasthenia gravis patients. PLoS One 2014;9(3):e91927. Go to original source... Go to PubMed...
    16. Punga A R, Punga T. Circulating microRNAs as potential biomarkers in myasthenia gravis patients. Ann N Y Acad Sci 2018;1412(1):33-40. Go to original source... Go to PubMed...
    17. Sakr M, Takino T, Sabit H, Nakada M, Li Z, Sato H. miR-150-5p and miR-133a suppress glioma cell proliferation and migration through targeting membrane-type-1 matrix metalloproteinase. Gene 2016;587(2):155-62. Go to original source... Go to PubMed...
    18. Scherrer N, Fays F, Mueller B, Luft A, Fluri F, Christ-Crain M, Devaux Y, Katan M. MicroRNA 150-5p improves risk classification for mortality within 90 days after acute ischemic stroke. J Stroke 2017;19(3):323-32. Go to original source... Go to PubMed...
    19. Yilmaz V, Oflazer P, Aysal F, Durmus H, Poulas K, Yentur SP, Gulsen-Parman Y, Tzartos S, Marx A, Tuzun E, Deymeer F, Saruhan-Direskeneli G. Differential cytokine changes in patients with myasthenia gravis with antibodies against AChR and MuSK. PloS One 2015;10(4):e0123546. Go to original source... Go to PubMed...
    20. Westerberg E, Molin C J, Lindblad I, Emtner M, Punga AR. Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance-based measures: A pilot study. Muscle Nerve 2017;56(2):207-14. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content